This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Oct 2019

Discover Roquette’s latest innovations and our new Biopharma Innovation Center!

Roquette works closely with customers in the development of innovative pharmaceutical formulations and new biopharma solutions.

With a multidisciplinary expertise and more than 50 products, Roquette offers an extended range of starches and derivatives, sugars & polyols, with an exceptional potential for meeting your needs, wherever you are, for oral dosage, nutraceuticals & OTC, Injectables, Dialysis & Specialty APIs and Biopharma.

When it comes to raw materials for cell culture or excipients in your formulation, you now have an alternative option: Manage risk with a steady supply of confidence for your materials from a source who has sole custody of the supply chain. Roquette now offers multi-compendial grade materials for both upstream and downstream applications.

To develop innovations in BioPharma and beyond, we have recently expanded our Research & Development and Customer Technical Service teams to include facilities in Singapore’s Biopolis international research and development center. Now our deep expertise in formulation and applications science enables us to provide customers with even more localized project support around the world and in-depth training on-site. Laboratory and pilot equipment at these facilities help customers address their technical and innovation challenges.

From oral dosage excipients (Rx, Gx, nutraceuticals & OTC) and biopharma materials to injectables and dialysis solutions, Roquette is holding itself to the highest industry standards - providing consistency and reliability across every ingredient.

To learn more about our latest innovations, come and visit us on our booth # 10.2 A66 and join us also for our cocktail party on Tuesday 5th at 17.00!

Mentioned Companies
Roquette America Inc.
View company profile

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.